2.42Open2.42Pre Close0 Volume2 Open Interest1.00Strike Price0.00Turnover341.40%IV8.23%PremiumDec 20, 2024Expiry Date2.16Intrinsic Value100Multiplier23DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type0.9609Delta0.0308Gamma1.42Leverage Ratio-0.0050Theta0.0005Rho1.36Eff Leverage0.0007Vega
23andMe Stock Discussion
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation
16 seconds ago, 4:30 AM PST
Via GlobeNewswire
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing first-in-class or best-in-class t...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million
Discontinues development of therapeutics division and commences strategic alternatives process for all in-house therapeutic programs
SUNNYVALE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics...
No comment yet